Donor Recognition

The Dana-Farber Campaign has enabled tremendous progress in cancer research and care, inspiring nearly 900,000 donors to defy cancer. The generosity of the Dana-Farber community cannot be overstated, and that is certainly true for Institute Trustees Michael Eisenson and Monica Chandra, chair and vice chair, respectively, of The Dana-Farber Campaign. Motivated by a desire to ease the burden of cancer for future patients, Eisenson and Chandra have dedicated their time and leveraged their expertise and connections for the entirety of this ambitious, multi-year fundraising effort.

As we look forward to celebrating the success of The Dana-Farber Campaign, both Trustees have made multimillion-dollar gifts to the endeavor, each reaffirming their commitment to Dana-Farber’s mission by supporting cutting-edge research with implications for cancer in its many forms. Furthermore, these special gifts establish a lasting legacy that both Eisenson and Chandra believe will be carried on by future generations of their families.

Eisenson’s involvement with the Institute first began more than 30 years ago, when the late David Livingston, MD, and former Institute President Baruj Benacerraf, MD, approached him with a funding opportunity. A respected business leader, Eisenson helped drum up support for early stage research at Dana-Farber. Soon after, in 1991, he was invited to join the Board of Trustees.

Supporting Dana-Farber’s mission was, and remains, personally meaningful to Eisenson. He lost his mother to cancer when she was only 45 years old, an experience that shaped his priorities. “I made a commitment to do what I could to help avoid this kind of loss for other families,” said Eisenson. “Every family has a story, and everyone can help. This is the way I chose to help.”

In 2021, Eisenson and his cousin Neil Mellen made a multifaceted gift in memory of Eisenson’s mother, Velma, and Mellen’s daughter, Nancy, who passed away from cancer when she was 52.

The gift provided substantial support for the Center for BRCA and Related Genes, one of the few centers in the world dedicated to the care for, prevention of, and research into BRCA-related cancers. Newly launched at the time, the center was one of the very first institutional initiatives that was identified as part of the campaign planning process.

Because BRCA-related genes are frequently mutated in multiple tumor types across cancer types—including breast, ovarian, pancreatic, and prostate, with an estimated 10-15% of these patients having inherited BRCA1/2 mutations—supporting the center was where Eisenson and Mellen felt they could make the biggest impact on cancer research.

Sadly, Neil Mellen passed away in January 2024. Eisenson, together with Neil’s foundation, is now carrying on the legacy they established with a new joint gift that will name The Mellen and Eisenson Family Center for BRCA and Related Genes, directed by Dipanjan Chowdhury, PhD, the Svanberg Family Chair; Judy Garber, MD, MPH, the Susan F. Smith Chair; and Panagiotis (Panos) Konstantinopoulos, MD, PhD. The gift will also establish the Velma Eisenson Chair for Clinical and Translational Research at Dana-Farber, with Konstantinopoulos serving as the first incumbent. Sustained support for the Nancy Ann Mellen Fund for Research and Clinical Trial Support Within the Center for BRCA and Related Genes, the David Livingston Early Career Investigator Awards, and the Pan-Mass Challenge will also be made possible.

“Neil and I were grateful to be able to focus our investment in an area that is of deep personal interest to us,” said Eisenson. “Dana-Farber is focused on developing real solutions in the most effective way possible, including through very meaningful collaborations among faculty members of different disciplines. My family and I know that treatments will emerge more quickly if we invest in this work—and more specifically, if we invest in Dana-Farber.”

Chandra first became involved with Dana-Farber almost two decades ago, when she joined a committee supporting the Susan F. Smith Center for Women’s Cancers. She speaks positively of this experience, as hearing firsthand from the experts at Dana-Farber sparked her interest in becoming further involved. She joined the Board of Trustees in 2015, and served as co-chair of the Trustee Campaign Planning Committee during the earliest phase of the campaign (2017–2021). Like Eisenson, Chandra and her husband, Nitin Nohria, are also members of the Dana-Farber Society, a special group that honors those who have made a legacy gift to the Institute.

Building on years of service to the Institute, Chandra and her husband recently made a gift to establish the Chandra Nohria Family Chair for AI in Cancer Research at Dana-Farber, which will provide permanent, endowed support for this important new frontier in scientific research.

Over the years, both Eisenson and Chandra have worked closely with Laurie H. Glimcher, MD, president and CEO of Dana-Farber and the Richard and Susan Smith Professor of Medicine, to determine the best, most impactful areas to support, and so they recognize the value in naming a Dana-Farber Chair. Doing so honors distinguished faculty members while simultaneously providing invaluable financial support that allows researchers to test their most innovative and high-risk ideas, accelerating the chance for groundbreaking discoveries.

“Both Michael and Monica have been instrumental in the success of The Dana-Farber Campaign,” said Glimcher. “Their leadership, generosity, and forward-thinking truly embody what is so very special about our Dana-Farber community, and ultimately provide a beacon of hope to everyone striving to defy cancer. I am deeply grateful to have committed leaders beside me as we forge ahead to change the course of cancer.”

“Around 1 in 5 people develop cancer in their life, and it remains a leading cause of death globally,” Chandra said. “The impact of what our researchers, doctors, and nurses do is felt not just in Boston or New England, but benefits patients worldwide.”

That is certainly true of the Chandra Nohria Family Chair’s first incumbent, Eliezer Van Allen, MD, chief of the Division of Population Sciences, whose work in computational biology and machine learning is helping to shape how artificial intelligence (AI) can be applied to cancer medicine and research.

The Chandra Nohria family’s support will fund a variety of studies in AI, including those aiming to further refine personalized drugs and applying machine learning to analyze patient samples and predict tumor response. Van Allen’s team is also leading the way in AI safety and equity, establishing protocols that aim to ensure that results from algorithms are better and more accurate than human analysts.

“We stand at the cusp of an exciting new era in cancer research,” Chandra added. “Unlocking the power of new technologies to accelerate cancer detection, treatment, and prevention will require tremendous investments. I am in awe and so grateful that almost a million people came together to support the vision of our campaign. Together, we will Defy Cancer!”

For Chandra, philanthropy is a family affair—her daughter Reva and son-in-law Zach recently set up a Giving Page to celebrate their wedding, inspiring guests to make a gift to Dana-Farber. Their effort has raised nearly $50,000 to date. The Chandra Nohria legacy will be felt for years to come at the Institute, as each generation takes up the cause in honor of their loved ones who have faced cancer—and all of the families and patients who will benefit from these innovative studies in the future.

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

In 1999, George O’Malley ran the Boston Marathon for what he called his “one and done.” He was happy he did it, but didn’t need to do it again. But then came 2000—some friends cajoled him into racing a second time. And then there was the next, and the next. In all, O’Malley has completed several “one and dones,” running 12 of them for the Dana-Farber Marathon Challenge (DFMC).

DFMC runners including O’Malley raised $8.8 million for The Dana-Farber Campaign this year, all of which benefits the Claudia Adams Barr Program in Innovative Basic Cancer Research, advancing promising ideas at their earliest stages so they can move forward toward discovery and cure.

Since 2015, O’Malley’s marathons have been in honor of his daughter Jill, who passed away from cervical cancer just two weeks before she could watch her father run that year.

“I ran in 2015—the team pushed me, pulled me, kicked me in the butt, and I made it across the finish line,” said O’Malley. “I felt so indebted to Dana-Farber, for Jill, that I said I needed to continue to run. The medical staff is superb, the strides in research, but beyond that—two of the parking attendants came to Jill’s memorial service. I can’t say enough about Dana-Farber.”

O’Malley, whose only goal each race is to “beat the street sweepers,” has raised more than $250,000 cumulatively for Dana-Farber as of 2024—a year he claims is truly his last time.

With similar longevity, the Mullaney family—this year’s top fundraising group—has had a family member run DFMC since 2013, when family patriarch Mark Mullaney was diagnosed with cancer. The Mullaney presence during every DFMC season since then has totaled more than $1 million.

“My father had almost five really healthy years due to Dana-Farber,” said Brian Mullaney, the eldest of Mark’s three sons, who are all DFMC alumni. “We were lucky on the one hand if you’re ‘glass half-full,’ like he was. His motto was ‘Find the fun,’ and to be able to get everyone together once a year to celebrate his outlook has been a fun way to keep him going.” This year, Brian crossed the finish line with his eldest daughter, Mackenzie, a college student who found the fun while devoting her weekends to train with her family.

Veteran marathoner Zea McKenzie first began running in 2014 after her mother passed away from lung cancer. She found catharsis in taking part in charity races, and set an ambitious goal for herself—completing 83 races, in honor of her mother’s age. She cleared that goal in just a few years and prepared to hang up her running shoes.

And then her son Tyler got sick.

Diagnosed with a rare translocation renal cell carcinoma in 2016, Tyler passed away a little over five years later at the age of 28. He wanted his mom to find joy and travel for him—and she has, by continuing her charity races all over the country—including her first DFMC in 2024.

“Someone once said to me that your loved one will continue to live until the last person says their name,” said McKenzie. “The pain never goes away, but turning all that pain into a purpose really helps. And when I saw my family cheering for me at mile 25, all I felt was sheer joy. I was emotional, but it was tears of joy.”

Since 1990, runners like O’Malley, McKenzie, and the Mullaneys have raised more than $132 million to benefit the Claudia Adams Barr Program, defying cancer in honor of their loved ones.

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

The Leukemia & Lymphoma Society (LLS) recently awarded more than $7.3 million in grants to 15 Dana-Farber researchers in its quest to better understand and find cures for blood cancers. Since 1949, LLS has invested more than $1.7 billion in groundbreaking research worldwide.

“The Leukemia & Lymphoma Society has funded some of Dana-Farber’s most innovative and exciting research on pediatric and adult blood cancers—research that has led directly to novel therapies that are now in the clinic,” said Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber and the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine. “In addition, LLS has supported the career development of some of our most promising trainees, many of whom are now leading investigators in the field.”

LLS has awarded translational research or career development grants to 12 Dana-Farber faculty members and fellows. A Discovery grant went to Sahand Hormoz, PhD, for his work to predict disease progression in myeloproliferative neoplasm patients, and an Equity in Access grant was awarded to Oreofe Odejide, MD, MPH, for a project to promote high-quality end-of-life care for blood cancer patients from historically marginalized racial and ethnic groups. Ted Williams Chair Kimberly Stegmaier, MD, received an LLS-PedAL award to expand her preclinical studies of new targeted therapies for

high-risk subtypes of childhood acute myeloid leukemia.

Five investigators received Translational Research Awards: Ruben Carrasco, MD, PhD; Constantine Mitsiades, MD, PhD; Margaret Shipp, MD, the Douglas S. Miller Chair in Lymphoma at Dana-Farber; Maximilian Stahl, MD; and Steven Treon, MD, PhD, director of the Bing Center for Waldenström’s Macroglobulinemia.

LLS Career Development Awards went to Inhye Ahn, MD;Stefan Bjelosevic, PhD; Johann-Christoph Jann,  MD; Christian Marinaccio, PhD; Adi Nagler, PhD; and Julia Paczkowska, PhD. Matthew Davids, MD, MMSc, received a Clinical Scholar Achievement Award in recognition of his significant contributions to the field since receiving his LLS Clinical Scholar Award in 2018.

With his award, Mitsiades is investigating ways of making immune effector cells, such as natural killer (NK) cells or engineered T cells, more effective against blood cancers such as multiple myeloma and leukemia. Although these therapies are initially successful, resistance often develops. Mitsiades and his team will use patient-derived samples to test drugs that can sensitize cancer cells to immune cell therapies.

Their findings could inform clinical strategies and identify subgroups of patients who might benefit most from combined or sequential treatments in future clinical trials. “This is a transformative time in the field of hematologic malignancies,” said Lee Greenberger, PhD, LLS’s chief scientific officer. “I have every confidence that the work led by Dana-Farber holds great promise for children and adults with blood cancers everywhere.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

In June, Dana-Farber Cancer Institute took a monumental step forward with the creation of the Alperin Family Chair in Neuro-Oncology. This endowed position—the Institute’s first chair dedicated to the field of neuro-oncology—was made possible through the extraordinary generosity of Tom and Marsha Alperin. David Reardon, MD, clinical director of the Center for Neuro-Oncology, has been appointed the first incumbent to hold this prestigious position.

This gift is a testament to the Alperins’ profound dedication to advancing the frontiers of medical research and patient care. Their transformative contribution follows their gift to establish the Clinical Accelerator Fund at Dana-Farber in 2023, a visionary initiative aimed at fast-tracking laboratory breakthroughs into the clinic toward lifesaving treatments. “We believe investing in people is a powerful path to changing the lives of everyone affected by cancer for the better,” said Tom Alperin. “We are thrilled to support a talented physician-scientist like David Reardon, while also investing in future generations of cancer researchers.”

Reardon, whose tenure at Dana-Farber began in 2011, is renowned for his innovative approach to immune-based therapies for brain and spine tumors, including leading some of the first trials of personalized therapeutic vaccines for high-grade brain tumors. His efforts have positioned Dana-Farber’s Center for Neuro-Oncology at the forefront of therapeutic discoveries for central nervous system tumors, which this chair will further elevate.

“I am inspired by Tom and Marsha’s generosity and vision in establishing this chair,” Reardon reflected. “Every day, we are learning more about how to outsmart cancer and this gift will help us accelerate our efforts and move closer to cures.”

The Alperins’ approach to philanthropy is strategic and heartfelt, driven by a commitment to paying it forward and pushing for a better future for all patients and their families. “The Alperin family’s investment is a powerful statement of hope and confidence in the future of neuro-oncology,” said Laurie H. Glimcher, MD, Dana-Farber president and CEO and the Richard and Susan Smith Professor of Medicine. “Their support is not just a gift to Dana-Farber; it’s a gift to everyone affected by brain cancer.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

In its mission to eradicate breast cancer, Susan G. Komen has invested nearly $1.1 billion in research since its founding in 1982. In 2023, Komen continued a longstanding partnership with Dana-Farber by awarding $2.3 million in new grants to Dana-Farber faculty members.

About 300,000 people in the U.S. are expected to be diagnosed with breast cancer this year, according to the American Cancer Society. “Research will cure cancer,” said Paula Schneider, Komen’s president and CEO. “The only way we move forward is to take the best from the laboratory and move it as quickly as possible into the clinic.”

This year, Komen awarded new research grants to Myles Brown, MD, director of the Institute’s Center for Functional Cancer Epigenetics and the Emil Frei III, MD, Professor of Medicine; Sarah Hill, MD, PhD; Ann Partridge, MD, MPH, founder and director of the Program for Young Adults with Breast Cancer, director of the Adult Survivorship Program, and the Eric P. Winer, MD, Chair in Breast Cancer Research at Dana-Farber; and Adrienne Waks, MD.

Additional esteemed Dana-Farber researchers supported by Komen in 2023 include Jose Pablo Leone, MD, director of the Program for Breast Cancer in Men; Jennifer Ligibel, MD, director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living; Nancy Lin, MD, MPH, director of the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases; Filipa Lynce, MD, director of the Inflammatory Breast Cancer Program; Elizabeth Mittendorf, MD, PhD, co-leader of the Parker Institute for Cancer Immunotherapy at Dana-Farber and director of the Breast Immuno-Oncology Program; Heather Parsons, MD, MPH; Kornelia Polyak, MD, PhD; and Sara Tolaney, MD, MPH, chief of the Division of Breast Oncology within the Susan F. Smith Center for Women’s Cancers at Dana-Farber.

Komen awarded Career Catalyst Research Grants to Hill and Waks. This important funding mechanism provides promising early career faculty with up to three years of protected research time under the guidance of a committee of mentors.

Hill is investigating a protein called HB01, which is widely expressed in triple-negative breast cancer (TNBC)—an aggressive, hard-to-treat form of the disease commonly found in people with familial BRCA1 gene mutations. Hill intends to better define the role of HB01 and validate it as a target for therapy in TNBC.

Waks is focused on improving treatments and outcomes for patients with HER2-positive breast cancer. Using blood and tissue samples from patients in a national clinical trial led by Dana-Farber, she will evaluate two antibodies that work partly by triggering the immune system’s natural killer cells to attack cancer cells coated with the antibodies. Her findings are expected to help oncologists choose the best antibody therapy for patients and inform strategies to overcome any resistance that may occur.

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

On the cusp of Chad Palumbo’s senior year of high school in 2022, he found himself in an unexpected place: Dana-Farber Cancer Institute. Chad had been diagnosed with rhabdomyosarcoma, a rare form of soft tissue cancer that appears mainly in children and teens.

Together with his parents, Keith and Jennifer, Chad navigated treatment for this diagnosis and learned about the urgent need to develop better, more targeted therapies for rhabdomyosarcoma. Due to a lack of funding from traditional sources, research for rare cancers like this relies on philanthropic support. The Palumbos were eager to discover what would be possible with additional funding.

“There was a study that was done just months before Chad was diagnosed that showed that undergoing chemotherapy for six months, instead of 12, was just as effective,” said Keith. “That was a meaningful change—without that study, his experience would have been a lot worse. We realized there was an opportunity to support additional research that could make an immediate difference for patients.”

With a generous gift, the Palumbos established the Palumbo Family Fund for rhabdomyosarcoma Research and the Palumbo Family Fund for Pediatric Clinical Care. The first portion of their gift will support efforts led by Kimberly Stegmaier, MD, to bring precision medicine, a treatment approach intended to identify and target specific mutations driving a patient’s tumor, to pediatric patients with rare sarcomas.

“While this approach has revolutionized treatment for other types of cancers, a lack of funding has slowed progress on rare pediatric cancers like rhabdomyosarcoma,” said Stegmaier, who is the co-director of the Pediatric Hematologic Malignancies Program and the Ted Williams Chair at Dana-Farber. “The Palumbos’ gift enables us to further study promising new therapies for this disease.”

The second portion of the family’s gift will help launch a first-of-its-kind program that provides pediatric patients with rare or difficult-to-treat cancers personalized, coordinated access to clinical specialists and cutting-edge research across Dana-Farber under the direction of Allison O’Neill, MD.

“The Palumbos’ gift will empower patients with rare cancers to take full advantage of Dana-Farber’s expansive clinical care infrastructure, and bring the latest scientific advances to them at the earliest point in their treatment journey,” said O’Neill.

Today, Chad is thriving as a student-athlete at Princeton University, where he plays lacrosse. The Palumbos are pleased to share that regular visits to Dana-Farber have continued to show clean scans.

“Walking into Dana-Farber, where they have full confidence in what you’re facing, there’s such a sense of comfort,” said Jennifer. “At one of the scariest times in your life, they know what they’re dealing with and are able to communicate in a way that gives you hope.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Transformative scientific discoveries don’t happen in a vacuum—they are built on a foundation of basic research. That is the focus of The G. Harold and Leila Y. Mathers Charitable Foundation, which recently awarded two Dana-Farber investigators $1.5 million to fund their research on unraveling the inner workings of human cells.

Edward Chouchani, PhD, is studying the function of lactate in cell proliferation. He has shown that it is a multifunctional signaling molecule playing a key role in controlling that process by binding to and inhibiting SENP1, a critical protein. For almost a century, lactate was thought to be an inert byproduct of glycolysis, one of the ways cells produce energy as they grow and divide. But Chouchani’s lab has discovered that lactate directly inhibits SENP1, with broad implications in cell biology and human physiology.

“I want to establish, for the first time, the mechanistic basis for how lactate is used as a general metabolic signal to control cellular function and cell states,” Chouchani said. “I expect these findings will prove highly relevant to cancer as well as several other areas of biomedicine.”

The foundation is also supporting the work of A. Thomas Look, MD, a pediatric oncologist at Dana-Farber. Look is investigating two tumor suppressor genes—Tet2 and Dnmt3a—found in leukemia and preleukemia syndromes. The proteins encoded by these genes control how the expression levels of many human genes are switched on and off. When Tet2 or Dnmt3a are inactivated by mutated blood cells, they can cause a condition known as clonal hematopoiesis of indeterminate potential (CHIP), which is an overgrowth of mutated cells in the blood. People with CHIP have an increased risk of leukemia, cardiovascular disease, and autoimmune diseases. There is no known treatment for the condition.

Look and his colleagues will analyze the gene expression and characteristics of individual cells to understand how the mutant cells become dominant and why they trigger inflammation. They will

also investigate whether changes of gene expression in mutant blood cells make them vulnerable to certain drugs that can specifically target and kill them without affecting normal blood cells.

“In previous work, we have identified some promising FDA-approved drugs that selectively killed the mutant blood cells,” Look explained. “Because of the generous funding from The Mathers Foundation, we will be able to test the efficacy of these compounds in laboratory models of CHIP. We will also gather important evidence to help us design early stage clinical trials aimed at reducing adverse outcomes for high-risk patients with CHIP.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

The Prostate Cancer Foundation (PCF) has awarded $1.45 million in grants to three Dana-Farber investigators researching more powerful treatments for the disease.

The California-based foundation honored Mary-Ellen Taplin, MD, with the 2023 Movember, Todd Boehly, Shmuel Meitar, Richard Merkin, MD, Marcel Claure-PCF Challenge Award in support of a project to determine whether aggressive treatment with androgen-receptor signaling inhibitors (ARSI) before surgery can result in disease-free survival. At the same time, Taplin and eight collaborators will analyze tumor specimens to identify biomarkers that could show which patients are most likely to experience a recurrence of their cancer after treatment with surgery and radiation.

“We anticipate these studies will lead to a paradigm shift in the management of patients with high-risk localized prostate cancer,” said Taplin, chair of the Executive Committee for Clinical Research at Dana-Farber. “If we can identify the patients whose disease is likely to spread, we can treat them more intensively prior to metastasis while allowing those at low risk to avoid additional therapy.”

PCF honored radiation oncologist David Yang, MD, with the 2023 Chris & Katia Oberbeck-PCF Young Investigator Award for his work using artificial intelligence (AI) and deep learning to uncover MRI and computational pathology biomarkers for localized prostate cancer.

“Our goal is to more accurately identify patients at elevated risk of having their disease recur who may benefit from more intensive treatments,” he said.

Postdoctoral fellow Varadha Balaji Venkadakrishnan, PhD, will apply the 2023 Kovler Family Foundation-PCF Young Investigator Award toward understanding the roles of two epigenetic regulators, EZH1 and EZH2, in neuroendocrine prostate cancer. “Because there are limited options for treating this lethal form of the disease, understanding its epigenetic underpinnings will result in novel treatment strategies,” he said.

“We are committed to the mission of ending death and suffering from prostate cancer,” said Howard Soule, PhD, executive vice president and chief science officer of PCF. “I look forward to the discoveries that these talented Dana-Farber scientists will make and to the innovative new therapies that may result.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

A generous $1 million gift to Dana-Farber’s Presidential Initiatives Fund from the Ambrose Monell Foundation enables Dana-Farber’s President and CEO, Laurie H. Glimcher, MD, to strategically deploy funds that bolster promising opportunities and meet unexpected needs. The Presidential Initiatives Fund has already made a powerful difference in the lives of patients by supporting clinical trials and faculty development, as well as advances in precision medicine, drug development, and digital innovation.

The Ambrose Monell Foundation, established in 1956, focuses on early stage research and social initiatives that strive to build a more creative, equitable, and innovative society. Since 2002, the foundation has given more than $6.6 million as a visionary supporter of Dana-Farber’s work. In recent years, including the current generous gift, this support has allowed Dana-Farber researchers to move the field of immunotherapy forward to better match patients with the treatment most appropriate to their cancer.

Among Dana-Farber’s immunotherapy priorities are recruiting scientific experts in emerging areas of research and treatment, such as CAR T-cell therapy—which involves giving patients modified versions of T cells from their own immune system—for pediatric brain tumors. A top physician-scientist who recently joined Dana-Farber draws on bioengineering techniques to focus on enhancing the potency and specificity of CAR T cells for children with cancer.

Another priority is the advancement of the Center for Personal Cancer Vaccines. Established in 2020, the center brings the best scientists together to develop new vaccines, test them in clinical trials, and examine the immune system response. Unlike vaccines that prevent disease, these therapeutic vaccines treat existing cancers by stimulating the immune system to recognize and kill tumor cells. Philanthropy such as the foundation’s allows Dana-Farber to progress with more investigator-initiated immunotherapy clinical trials and establish the research and infrastructure to generate such personalized vaccines.

By encouraging strategic risk-taking and rewarding experimentation and new ideas, the Ambrose Monell Foundation enables Dana-Farber to capitalize on our collective expertise to develop a new generation of innovative cancer-fighting immunotherapies tailored to the specific needs of our patients.

“Innovation and the hope for a better tomorrow are our core,” said Ambrose Monell, president, director, and treasurer of the foundation. “That is why we are proud to continue funding the groundbreaking work happening every day at Dana-Farber, where patients get the most leading-edge care and the research is changing the lives of cancer patients everywhere.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Despite advancements in cancer research, prevention, early detection, and treatment, groups that are economically and socially marginalized continue to bear a disproportionate burden of cancer incidence and mortality. According to research by Dana-Farber’s Pediatric Oncology department, one in five of the pediatric patients treated at Dana-Farber’s Jimmy Fund Clinic face food insecurity at the time of their cancer diagnosis. This number only increases during cancer treatment, as the financial burden of treatment continues to impact families.

To help combat food insecurity among cancer patients, Stop & Shop made a $1 million gift to establish the Dana-Farber Cancer Institute Therapeutic Food Pantry.

The creation of the Therapeutic Food Pantry represents an equity-driven, cross-sector partnership to eliminate barriers that disrupt access to food and impact social determinants of health. The funds will be managed under the direction of Deborah Toffler, MSW, LCSW, senior director of Patient Care Services at Dana-Farber.

“We are so grateful to Stop & Shop for this gift,” said Toffler. “The stress of a cancer diagnosis and treatment on top of food insecurity can be incredibly challenging. The Therapeutic Food Pantry will help provide nourishment and nutrition to our most vulnerable patients.”

Upon opening, the Therapeutic Food Pantry will initially focus on serving pediatric patients and their families before expanding to the adult patient population. It is anticipated that 140 patients and families will be served during the first phase of the program, based on the number of families who currently receive grocery cards through Dana-Farber’s Pediatric Resource Program. The initiative will provide families with access to shelf-stable and perishable food options. In addition, faculty will collaborate with clinicians and nutritionists at Dana-Farber’s Leonard P. Zakim Center for Integrative Therapies and Healthy Living to ensure that patients and their families receive food options that are aligned with any pertinent cancer-specific nutrition recommendations. A vision for the future of the pantry includes a rooftop garden offering both fresh fruits and vegetables and a therapeutic space for patients, caregivers, and staff on the main Dana-Farber campus.

“We’re committed to addressing hunger in every community we serve,” said Gordon Reid, president at Stop & Shop. “We are thrilled that the establishment of the Therapeutic Food Pantry will make a profound difference to cancer patients and their families.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Peggy and Greg Strakosch are visionaries who keep their eyes trained on the horizon for the very early stages of the next critical factor that warrants attention and support. Their recent gift of $1 million to Dana-Farber Cancer Institute will support the collaborative work of Dipanjan Chowdhury, PhD, the Svanberg Family Chair at Dana-Farber, chief of the Division of Radiation and Genome Stability, and co-director of The Mellen and Eisenson Family Center for BRCA and Related Genes, to take the next step in producing a blood test that can identify patients most at risk for developing a BRCA-related cancer, such as breast and ovarian cancer. This new early detection blood test using microRNAs could become the basis for a more accessible, affordable, and comprehensive way to identify an inherited risk of cancer.

“In speaking with Dr. Chowdhury about this next step in his research, it seems obvious that this could be a game changer,” said Greg and Peggy Strakosch. “It’s a compelling place to invest our money because it can have a significant impact on patients. When cancer is detected early, the success rate for cure is so much higher.”

Inherited BRCA1 and BRCA2 gene mutations can increase risk or predisposition for certain types of cancer, including ovarian, breast, pancreatic, and prostate. By identifying who carries these mutations and is at greatest risk, doctors can provide preventative or early treatment. However, genetic testing is currently required to discover who carries these mutations, and it can be costly and inaccessible to many people. But the blood test that Chowdhury and his colleagues at Brigham and Women’s Hospital are treating can reveal which BRCA-carriers are at most risk for developing cancer in a more accessible way. With the latest funding from the Strakosches, Chowdhury and his colleagues will take the next step in validating this test. They will analyze a cohort of 1,200 patient blood samples to identify a unique signature that will indicate an onset of cancer in patients who carry a BRCA mutation.

“My vision is to reimagine the global standard of cancer detection and change the lives of patients through improved cancer screening and prevention,” said Chowdhury. “The only way to realize this goal is with the support of generous donors like Peggy and Greg, who share my vision for a future where testing for cancer risk is as easy as testing for heart disease or diabetes.”

This vision to defy cancer doesn’t end with Greg and Peggy; their adult children have inherited their same energy and commitment to framing a world without cancer and participate in the Pan-Mass Challenge with their team called Team Detect Me if You Can.

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Wycliffe “Wyc” Grousbeck and Emilia Fazzalari are firm believers that “good things don’t come easy.” As philanthropic and entrepreneurial leaders in the Boston community, they seek out innovative and exceptional people who are tackling groundbreaking endeavors that are simply too compelling to refuse.

This approach led them to make an extraordinary gift to help establish the Centers for Early Detection and Interception (CEDI) at Dana-Farber Cancer Institute, which launched in December 2023. Their transformational support is empowering CEDI’s leadership—Irene Ghobrial, MD, director of the Center for Early Detection and Interception of Blood Cancers and Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber; Betsy O’Donnell, MD, director of Early Detection and Prevention of Malignant Conditions; and Sapna Syngal, MD, MPH, director of research, Division of Cancer Genetics and Prevention and of Strategic Planning for Prevention and Early Cancer Detection—to guide a radical shift in the paradigm of cancer treatment through CEDI. This first-of-its-kind, integrated clinic brings together clinicians and researchers across cancer types to advance early detection of precancerous conditions, identify individuals at increased risk, and develop new and powerful interventions to stop cancer in its tracks.

The foundational investment from Grousbeck and Fazzalari ensures that Dana-Farber can build on its existing expertise in screening, risk assessment, and interception to deliver proactive care to more patients. Their support will enable CEDI to develop diagnostic strategies and advance cutting-edge technologies, expand biobanking resources, accelerate and enhance the use of vaccines and other immunotherapies, and ultimately create targeted patient monitoring plans that help prevent cancer from arising in individuals with increased risks. “The key word is prevention,” says Fazzalari, who is a co-founder and executive chairperson of Cincoro Tequila and serves on multiple boards in Boston and New York City. “The ability to identify those at risk, understand one’s predispositions, and make lifestyle changes to avoid cancer is an ideal that is now within reach. There is still a long way to go, but the result is so important and worth pursuing.”

Laurie H. Glimcher, MD, Dana-Farber president and CEO and the Richard and Susan Smith Professor of Medicine, believes this gift and CEDI have the potential to change the trajectory of cancer diagnoses for patients and families in Boston, New England, and around the world. “This visionary contribution to The Dana-Farber Campaign will shape the field of cancer medicine for the years and generations to come,” says Glimcher. “Their generosity is helping Dana-Farber meet a critical turning point in global cancer science: shifting from a reactive to proactive standard of care model that is personalized to meet individual needs.”

Looking to the future, Grousbeck, who is the managing partner, governor, and CEO of the Boston Celtics, is optimistic about the path ahead. “Dana-Farber has their sights on an exciting goal that will save many lives and we have the utmost confidence in the team to take us there,” said Grousbeck. “The building blocks to cancer prevention and early detection are in place and we want to help pave the way for people to get there faster while ensuring everyone has equitable access.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

The Damon Runyon Cancer Research Foundation has awarded more than $3.2 million in grants to nine early career investigators at Dana-Farber, including Mounica Vallurupalli, MD, who was named the foundation’s first Damon Runyon-David M. Livingston, MD, Physician-Scientist. The late David Livingston, MD, was a prominent expert on the molecular origins of breast and ovarian cancer who held many leadership positions at Dana-Farber for nearly 50 years.

The foundation, founded in 1946 in memory of the iconic sportswriter and journalist Damon Runyon, has invested more than $450 million in nearly 4,000 scientists who are conducting “audacious and ambitious” research into the prevention, diagnosis, and treatment of cancer. It has supported Dana-Farber investigators with more than $26 million to date.

In addition to Vallurupalli’s award, the foundation made the following grants in 2023: the Dale F. Frey Award for Breakthrough Scientists to Benjamin Stinson, PhD; Physician-Scientist Training Award to Nina Weichert-Leahey, MD; Pediatric Cancer Fellowships to April Apfelbaum, PhD, and Costanza Lo Cascio, PhD; a Clinical Investigator Award to Sylvan Baca, MD, PhD; and Postdoctoral Research Fellowships to Kheewoong Baek, PhD, and Anders Dohlman, PhD. The foundation also extended further Damon Runyon- Rachleff Innovation Award funding to Srinivas Viswanathan, MD, PhD.

Vallurupalli is investigating proteins called splicing factors, which when mutated, can cause certain blood cancers to form. Her research focuses on the role of splicing dysregulation in the development of myelodysplastic syndromes and leukemia, which could yield new therapeutic strategies to defeat these cancers.

With his award, Stinson is studying the mechanisms that cells use to repair broken DNA—non-homologous end joining (NHEJ) and homologous recombination (HR). When these are defective, cancers can result. Stinson is researching how HR suppresses cancer when it is working properly and how cancer cells become resistant to treatment when it is not.

Weichert-Leahey will use her grant to test a new drug against neuroblastoma, a cancer that originates in the adrenal glands and is most common in infants and children under 5. She will test a promising small molecule drug, PF-9363, together with isotretinoin to see whether the combination therapy can improve outcomes for children with high-risk neuroblastoma.

“We take great pride in enabling brilliant young scientists to take risks and experimentally address important and bold questions in cancer research,” said Yung Lie, PhD, president and chief executive officer of the Damon Runyon Cancer Research Foundation. “I have no doubt that these Dana-Farber projects will yield exciting results.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Longtime Dana-Farber supporter Conquer Cancer,® the ASCO Foundation, recently awarded $1.45 million to support seven researchers pursuing projects in a wide range of disease areas.

Ana Garrido-Castro, MD, and Guilherme Nader-Marta, MD, are both leading studies into treatments for metastatic triple-negative breast cancer (TNBC), an aggressive form of breast cancer for which few targeted treatments exist. Garrido-Castro is evaluating the use of antibody-drug conjugates (ADC), which are antibodies that carry potent chemotherapy and bind to specific targets on cancer cells, thereby delivering chemotherapy in a targeted manner to tumors. Garrido-Castro is now conducting a multicenter, phase 2 trial that aims to identify which patients will benefit most from sequential ADC therapy.

Nader-Marta has found a potential drug target in TNBC—a protein called prostate-specific membrane antigen (PSMA) which often presents in high levels in patients with metastatic TNBC. Nader-Marta will test the efficacy of a drug that has already demonstrated efficacy in patients with prostate cancer.

With her funding, Elizabeth Carstens, MD, is refining the use of CAR T-cell therapy in patients with advanced multiple myeloma. This therapy entails collecting T cells from patients and altering them outside of the body to produce chimeric antigen receptors (CAR) that can target cancer cells. Carstens is testing a method to reprogram T cells so that patients can generate them inside the body, reducing the time needed for the procedure.

Narjust Florez, MD, is leading a study into the effects of immune checkpoint inhibitors on fertility in women of childbearing age receiving treatment for early stage lung cancer and melanoma, with the goal of enhancing patient-provider communication around these topics and creating interventions to mitigate the negative effects of these therapies.

Riaz Gillani, MD, is studying inherited genetic changes in DNA damage repair genes that increase risk for Ewing sarcoma—one of the most common bone and soft tissue cancers that affects children and adolescents—in order to improve prevention methods, predict treatment resistance, and design more informed treatment plans.

ER-positive HER2-negative breast cancer is one of the most common forms of breast cancer found in male patients. Jose Pablo Leone, MD, is leading a multicenter study that aims to expand endocrine therapy options for this patient population.

Jaclyn LoPiccolo, MD, PhD, is analyzing the genetic changes associated with young-onset lung cancer to help identify patients at higher risk for developing the disease and predict how the cancer will respond to targeted treatments.

“We’re so proud to support these researchers as they pursue innovative projects across the cancer spectrum,” said Conquer Cancer CEO Nancy Daly, MS, MPH. “By supporting these physician-scientists, we accelerate lifesaving research and empower more people to conquer cancer.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

For nearly a decade, the Schaubert family has been a dedicated supporter of lung cancer research at Dana-Farber. Building on a legacy of giving begun by her late husband, Eileen Schaubert has generously pledged $1.5 million to establish the Schaubert Family Endowed Fellowship, a gift that provides immediate and future support for the next generation of lung cancer experts while furthering pioneering research overseen by David Barbie, MD, director of the Lowe Center for Thoracic Oncology.

Steve Schaubert was inspired to make the family’s first gift to Dana-Farber following his own successful treatment for small cell lung cancer shortly before he passed away of unrelated causes in 2015. In the years following, Steve’s wife, Eileen, along with their daughters Suzanne Schaubert Thornfeldt and Amy Schaubert Brown, has built on his commitment through further support of Barbie’s research. With this new gift, the Schauberts are funding the work of early career physician-scientists dedicated to lung cancer research at Dana-Farber, under Barbie’s direction.

“As we’ve learned more about Dr. Barbie’s work, we’ve come to understand the importance of fellows in cancer research,” said Schaubert. “These young investigators are bringing their valuable knowledge and experience to lung cancer research and patient care at Dana-Farber, and we want to ensure Dr. Barbie is able to look to the future knowing he will have fellowship funding in perpetuity.”

In addition to providing critical research support, philanthropic investments like the Schaubert Family Endowed Fellowship help Dana-Farber attract the brightest minds in the field and prepare a new generation of physicians and scientists to become leaders in clinical and laboratory investigation and patient care. With steady funding provided by the endowment, investigators and clinicians can focus on spending more time with patients and translating findings into new treatment protocols that can help patients around the world.

“Fellowships backed by philanthropic funding allow early career physician-scientists to launch their careers in lung cancer oncology at Dana-Farber, while simultaneously bringing their new, unique perspectives to our lab,” said Barbie. “I am grateful for the Schauberts’ visionary support in helping us pursue more effective treatments for lung cancer patients.”

“Our family’s experience at Dana-Farber has given me full confidence in the dedication and capabilities of its people,” Eileen says. “We feel so fortunate that we are able to help support lung cancer research at Dana-Farber in this way.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Philanthropy has transformative power to address society’s intractable challenges. The Gray Foundation is committed to this goal and, with two grants totaling nearly $6 million, is harnessing this power for good through The Dana-Farber Campaign. Co-founded by Jon Gray, president and chief operating officer of Blackstone, one of the world’s leading investment firms, and his wife, Mindy, the Gray Foundation has funded close to $200 million in BRCA-related research since 2012. These latest grants to Dana-Farber are part of a recent $25 million initiative that awarded grants to seven research teams.

Individuals who inherit a mutated BRCA gene are 60% more likely to develop certain cancers compared to the general population. The Gray Foundation recently awarded grants to multi-institutional, multi-disciplinary teams studying BRCA, including those led by Judy Garber, MD, MPH, chief of the Division of Cancer Genetics and Prevention and the Susan F. Smith Chair at Dana-Farber; and Dipanjan Chowdhury, PhD, chief of the Division of Radiation and Genome Stability and the Svanberg Family Chair at Dana-Farber, who are also codirectors of the Institute’s Center for BRCA and Related Genes. The goal of these awards is to maximize collective impact so each new discovery leads to further advances and innovations toward the prevention, early detection, and interception of cancer.

Previous research by Garber suggests that PARP inhibitors (PARPi) and similar agents that treat certain cancers by targeting the body’s DNA repair system may reduce, or even prevent, future development of precancerous lesions driven by BRCA mutations into breast or ovarian cancer. Now, Garber is collecting healthy breast or fallopian tissue from patients who received PARPi therapy for another non-metastatic BRCA-related cancer. She and her collaborators will use advanced scientific profiling techniques to comprehensively evaluate the effects of PARPi and compare PARPi-treated tissue with healthy tissue from BRCA mutation carriers not treated with PARPi to search for biomarkers or other indicators associated with the progression of BRCA-related cancer.

About half of people who carry a BRCA mutation have a family history of cancer that would indicate genetic testing. Despite this, only one in 10 of the estimated 1 million carriers in the U.S. is aware of their status. Furthermore, current tests for ovarian cancer only detect the disease at advanced stages. Chowdhury has previously identified a set of 10 microRNAs (miRNAs), small molecules that affect gene regulation, whose presence in blood is associated with BRCA mutations. The miRNAs can be used to detect the mutations in individuals from high-risk families to help address these gaps in testing and early disease detection. Chowdhury will study patient blood samples taken over time with two aims: first, to test the miRNA set in predicting breast cancer cases retrospectively and better understand the clinical lead time to diagnosis, and second, to explore the possibility of other, currently unknown inherited drivers of cancer predisposition being correlated with this miRNA set.

Ultimately, these investigations could significantly improve cancer surveillance and prevention. “Our goal is to support the best minds in cancer research studying BRCA-associated pre-cancer and early cancerous lesions,” said Mindy and Jon Gray. “Dr. Garber’s and Dr. Chowdhury’s world-class projects stand to transform outcomes for individuals and families with BRCA-related mutations.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Despite all she’s been through, Jill Altman considers herself lucky. For nearly half her life, Jill has had run-ins with cancer—starting when she was diagnosed with low-malignant potential ovarian cancer in 1996 at just 22 years old. Jill received a total hysterectomy and at first was told she didn’t need chemotherapy. When that recommendation shifted and Jill’s family began to encounter conflicting advice from doctors close to home in New York, a friend suggested they go to Dana-Farber. There, a meeting with Ursula Matulonis, MD, chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at Dana-Farber, changed everything.

“Up until that point, no one had taken the time to explain anything to us,” said Jill’s father, Frank Altman. “The culture at Dana-Farber was so incredible. They were willing to listen. They cared.” Jill agreed. “We were immediately comfortable at Dana-Farber,” she said. “We knew we were home.”

Matulonis was familiar with Jill’s rare form of cancer and, along with colleagues including Michael Muto, MD, director of the Gynecologic Oncology Fellowship Program at Brigham and Women’s Hospital, Matulonis confirmed that Jill did not need chemotherapy. Instead, she recommended that Jill continue to be seen and go on living her life. Jill did just that, soon getting married and becoming a stepmother.

In 2012, 16 years after her initial surgery, Jill was diagnosed with low-grade serous carcinoma and underwent surgery to remove her spleen. Then in 2018, she developed pain in her clavicle and felt a lump. Jill and her family once again received frightening and conflicting recommendations. But this time, they knew who to trust.

“We went back to Ursula and she immediately knew what to do,” said Jill. “It sounds weird to say, but I had the best time. Dana-Farber is a fantasy land.”

Jill received pinpoint radiation, working with Matulonis and radiation oncologist Larissa Lee, MD, who spent hours on the phone with Jill explaining this treatment. The approach worked wonderfully, and Jill has been healthy ever since. Sadly in 2021, Lee passed away from gastrointestinal cancer—a devastating loss to many, including Jill.

Inspired by Lee, Matulonis, and her care at Dana-Farber, Jill decided to make a significant bequest to the Institute in memory of Lee. Half of the funds will support Matulonis’ gynecologic oncology research, and the other half will provide crucial unrestricted support to drive key Institute initiatives. Jill hopes for more research about her specific type of cancer and more happy outcomes.

“I wanted to have a positive impact on other women going through this and knew I could do something,” said Jill. “We believe in Dana-Farber.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

More than 10 years ago, Steven Treon, MD, PhD, and his colleagues were the first scientists to discover that MYD88 mutations, which occur in more than 95% of patients with Waldenström’s macroglobulinemia (WM), rely on the BTK protein to function. This research led to Food and Drug Administration approval of ibrutinib, the first drug to specifically treat this slow-growing form of non-Hodgkin lymphoma.

With grants totaling more than $1.2 million from the International Waldenstrom’s Macroglobulinemia Foundation (IWMF), Treon and his colleagues from Dana-Farber’s Bing Center for Waldenström’s Macroglobulinemia are delving deeper into the biology and genetics of WM in hopes of developing new, more effective treatments for patients.

Treon, director of the Bing Center, is using an IWMF Legacy Grant to develop drugs called PROTACs that use the body’s own cellular disposal system to rid itself of proteins essential to the growth and survival of WM cells. One of the proteins Treon identified is HCK, a powerful survival signaling molecule that is turned on by MYD88. To identify possible HCK degraders, Treon and his team will use a new approach to drug development called chemoproteomics, which identifies potential compounds that bind to cancer-causing proteins and degrades them.

“In these studies, we will focus on drugs that directly hit and degrade HCK,” says Treon. “By doing so, we hope to broadly shut down the signal cascades that allow WM cells to grow and survive. We are grateful for the IWMF’s generous support of this important work.”

As part of the IWMF/LLS Strategic Research Roadmap Initiative, Zachary Hunter, PhD, the Bliss Family Investigator in Waldenström’s Macroglobulinemia, is studying novel isoforms—alternate forms of proteins that can perform related but often distinct biochemical functions—and tumor evolution in WM. Specifically, he will investigate how abnormal isoforms relate to the evolution of disease subtypes. Identifying these targets may lead to more personalized therapy approaches.

Maria Luisa Guerrera, MD, previously discovered that WNK2 is one of the top dysregulated genes in WM. With a Robert A. Kyle Career Development Award from IWMF, she will continue to study WNK2 to better understand the different ways WM cells improperly regulate the gene and how these changes affect WM cells’ behavior and growth. Her findings may lead to new treatment strategies that target altered forms of WNK2.

“All of us with the IWMF are extremely proud of our ongoing partnership with Dana-Farber’s Bing Center and the funding we have provided to support research conducted by Dr. Treon and his incredibly talented team,” said Newton Guerin, IWMF president and CEO. “Collectively, their work has resulted in scientific discovery that has led to more and better therapies for the global WM community.”.

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer researchers, driving the pursuit of bold and innovative science toward earlier detection and better treatments, and transforming pancreatic cancer into a curable disease. A hallmark of the foundation’s unique research strategy, the LABS (Lustgarten Advancing Breakthrough Science) Program, provides long-term funding to promote the development of innovative ideas and speed the pace of discovery by incentivizing interdisciplinary team science.

Through the LABS program, the Lustgarten Foundation awarded a grant of nearly $5 million to Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber, and his team of physician-scientists. With this generous funding, they are working to uncover new ways of detecting the disease in its earliest stages—when it can be most easily treated—and developing more effective therapies for patients whose cancer has progressed.

“We are exceptionally grateful for the foundation’s tremendous support, which is helping us make progress against this devastating disease,” said Wolpin. “We owe many of the major strides in pancreatic cancer research to the foundation’s influential advocacy and research funding, and we are beyond grateful for their enduring leadership.”

Together with Andrew Aguirre, MD, PhD, and Jonathan Nowak, MD, PhD, Wolpin is leveraging this grant to propel three projects. The first focuses on developing novel therapeutic approaches by exploring how pancreatic tumor cells adapt following treatment by chemotherapy or KRAS inhibition, a precision therapy that is currently in clinical trials for patients with pancreatic cancer. The team is now conducting in-depth analyses of tumor cell behavior to determine how these complex biological mechanisms might be targeted to inform the development of new therapies.

The second is examining the heterogeneous cellular makeup within pancreatic cancer tumors and their surrounding microenvironments, focusing on how these characteristics vary between primary and metastatic tumor sites. The team is using advanced profiling technologies to spatially map these differences, which promise to inform future therapeutic strategies that account for a tumor’s specific context.

Finally, Wolpin and his team are exploring new approaches to detect pancreatic cancer earlier. Pancreatic cancer is typically discovered at an advanced stage, when treatment options are generally not curative, but recent studies have shown that metabolic changes could signal early cancer formation. To test this hypothesis, Wolpin and his team are leading studies in patients and laboratory models to formulate a comprehensive approach to early detection, using clinical data, blood markers, and radiologic tests.

“The Wolpin-led lab at Dana-Farber Cancer Institute is a critical hub for translational research,” said Linda Tantawi, CEO of the Lustgarten Foundation. “We are proud to support Dr. Wolpin and his team as they push for innovation in pancreatic cancer research, led by a patient-centered mission and science-driven strategy.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

In cancer research, hope can be realized in how we innovate. Inventive clinical trials can lead to novel approaches and new, accessible medicines that ultimately bring better outcomes to patients. This dynamic is especially true in pancreatic cancer, a historically challenging form of cancer to treat with survival rates that have remained stubbornly low over time. It is a disease that demands urgent innovation, attention, and resources to develop more treatments for patients.

Beth and Rich Kendall hope to do just that. With a generous donation of $1 million, Beth and Rich established the Kendall Family Fund for Innovative Pancreatic Cancer Therapies. Managed under the expert direction of Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber, the fund will directly fuel clinical trials for pancreatic cancer while also bolstering new treatments and therapies for gastrointestinal cancer patients. Wolpin will also be able to prioritize the recruitment of key personnel who are essential to the advancement of research and clinical trials. This multi-faceted approach places innovation at its core by supplying resources across disciplines to accelerate progress in the field.

“We believe in Dana-Farber’s commitment to excellence and their relentless pursuit of new solutions for patients,” said Rich. “It is with great optimism that we look forward to the advancements our partnership will bring.”

After witnessing Dana-Farber’s quality of care firsthand during Beth’s father’s treatment for pancreatic cancer, Beth and Rich were inspired to take an active role in supporting Dana-Farber’s efforts to understand, prevent, and treat pancreatic cancer. This latest gift represents one of numerous contributions from the Kendall family, cementing their family’s commitment to pancreatic cancer research.

“We feel a deep responsibility to contribute to a future where pancreatic cancer no longer takes away precious moments from families,” said Beth, “This fund is a tribute to the resilience and courage of those battling this illness. It is our hope that through innovative research and cutting-edge treatments, we can turn the tide against pancreatic cancer and offer new hope to patients and their families.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Steve and Joan Clark made their initial investment in artificial intelligence research in 2017, driven by a deep-seated conviction that this technology would revolutionize the world, particularly in the realm of health care and cancer care. And Dana-Farber agrees.

Recent advancements in AI and machine learning have transformed the study of diseases including pancreatic cancer, which is notoriously difficult to treat. Sadly, nearly 80% of patients with pancreatic cancer are diagnosed at an advanced stage when the cancer has already spread, rendering surgical intervention impossible. However, Dana-Farber investigators are exploring AI applications in early detection that could lead to improved outcomes.

In 2018, a groundbreaking project led by Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber, centered on analyzing annotated images on CT scans of body composition in pancreatic cancer patients. Their findings unveiled a significant trend: patients frequently displayed indications of skeletal muscle wasting upon diagnosis.

Recognizing the need for more extensive image analysis, Michael Rosenthal, MD, PhD, a radiologist and collaborator with Wolpin, developed an AI tool to automate the reading of these scans. Since then, the tool has analyzed over 100,000 CT scans, a task that would have been nearly impossible if conducted solely by humans. The ultimate goal of this work is to identify signals—whether in blood, scans, or medical records—that could facilitate earlier detection of pancreatic cancer.

To build on this foundation and propel this vital research forward, the Clarks recently gave $1.14 million to endow Wolpin’s work in AI and machine learning, specifically targeting gastrointestinal cancers. The Clarks strategically allocated these funds, recognizing that while AI holds immense promise as a tool, establishing the necessary infrastructure requires substantial financial investment. “The Dana-Farber Endowment offers a natural avenue for AI technology,” Steve explains. “The initial capital is invested, generating income annually in perpetuity. By combining an endowment with current-use funding, we have a unique opportunity to spearhead significant advancements in this field.”

“We are very grateful for Steve and Joan’s continued partnership and generous support of new ideas and avenues of research that will propel the field forward,” said Wolpin. “The Clark Family Artificial Intelligence Endowment will help advance research to utilize artificial intelligence and machine learning to break new ground in developing better, more effective treatments and methods of cancer prevention.” For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Maura Shaughnessy has been a steadfast Pan-Mass Challenge (PMC) rider for nearly 31 years, raising more than $2.8 million, but one thing she loves even more than cycling is her brother Frank. Maura and Frank come from a family of cancer survivors, and they are all too aware of the need for effective and long-lasting therapeutic discoveries. When Frank was diagnosed with stage IV kidney cancer in October 2020, Maura instantly connected him with Dana-Farber Cancer Institute.

Inspired by the work of fellow PMC rider Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber and the Jerome and Nancy Kohlberg Professor of Medicine, Maura and her husband, Bernie Regenauer, established the Frank Shaughnessy Kidney Cancer Research Fund in 2021. Between 2021 and 2023, $1.67 million was raised with help from their family’s donation, as well as donations raised by Maura and Team MFS.

Frank’s treatment initially provided good results, but unfortunately he contracted COVID-19 in the fall of 2023, and needed to stop treatment for six weeks while he recovered. At his next scan, his care team discovered that the kidney cancer had spread to his lungs. Given this devastating development, Frank was placed on a brand new FDA approved drug, but that too was ultimately unsuccessful.

“All we can do now is hope and pray,” Maura said. “And I am hopeful that we will receive some good karma since Dr. Choueiri is just as passionately involved with Frank’s care now as he was on day one.”

With the hope for a brighter future for cancer patients, Maura and Bernie made a new gift of $1 million to establish the Frank Shaughnessy Endowed Fellowship in Kidney Cancer. This fellowship will complement the previously established research fund in Frank’s name and will afford Choueiri the ability to hire a renowned and respected researcher to work alongside him in the lab to demystify the biology of kidney cancer, how it proliferates, and to develop novel treatment strategies, such as natural killer cells and immunotherapies.

“Maura and Bernie’s endowed fellowship will allow us to double the number of fellows on our team while also educating and fostering the next generation of physician-scientists who will continue to expand this work,” Choueiri said.

“My brother hasn’t had a lot of breaks along this cancer journey— one could say he really hasn’t had any,” Maura said. “But if we can do something that potentially gives him and those who follow him, another option down the road, that’s pretty good money spent in my mind.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

Year after year, the Palm Beach community demonstrates their unwavering commitment to Dana-Farber in many ways including through the Palm Beach Annual Appeal. This year the community, led by Phyllis and Paul Fireman, came together to contribute more than $1 million to the appeal in support of groundbreaking scientific research and exceptional care at the Institute.

Funds raised through the Palm Beach Annual Appeal are an important source of unrestricted support—a crucial priority for The Dana-Farber Campaign. Flexible funds play a key role in programs across the Institute, propelling innovative early stage research, speeding new drugs into clinical trials, and empowering Dana-Farber to continue serving our patients’ physical, emotional, psychological, and spiritual needs.

“We have been part of the Dana-Farber family for over 40 years and because of this, we can say with complete confidence that Dana-Farber is the best place for lifesaving treatment and compassionate care,” said Phyllis and Paul Fireman, chairpersons of this year’s Palm Beach Annual Appeal. “We are proud to have led the 2024 Palm Beach Annual Appeal and are grateful for the support of our community to bring us one step closer to a world without cancer.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less

The Cancer Research Institute (CRI) has awarded nearly $1.5 million in grants to Dana-Farber in support of investigations into how immunotherapy can be used to defeat difficult-to-treat and incurable cancers.

Founded in 1953 to fuel discovery and development of powerful immunotherapies for all cancers, the New York-based organization has invested $515 million in research scientists around the globe. In 2023, it awarded a multiyear Lloyd J. Old STAR grant to Dana-Farber pediatric oncologist Robbie Majzner, MD, for his work to identify and test new immunotherapies for children with cancer. And it chose Maxime Meylan, PhD, for a CRI Immuno-Informatics Fellowship for early career scientists.

Majzner’s research has three main goals: to develop and deploy safer and more effective chimeric antigen receptor (CAR) T cells; to explore the biology of GD2, a little-understood sugar expressed on the tumor cells of certain childhood cancers that suppresses immune function; and to conduct early phase clinical trials of immunotherapies in children.

CAR T cells have revolutionized the treatment of bloodborne cancers, but have yet to show substantial benefits in patients who have solid tumors. By studying how these cells propagate their internal signals, Majzner’s lab has co-opted molecules from inside the cell to alter the efficacy and specificity of these powerful therapeutics.

Pediatric oncologists have been targeting GD2 for more than two decades, but how it is regulated has not been well understood. Majzner is investigating its biology and how anti- GD2 therapies might be effectively deployed against a wide range of cancers.

“My goal is to utilize basic biologic discoveries to develop effective immunotherapies for children with cancer—especially those that are now considered incurable,” said Majzner.

Meylan, an immunologist and computational biologist, is researching the factors that influence treatment effectiveness in triple-negative breast cancer (TNBC), which is aggressive and difficult to treat.

He will use advanced imaging techniques to study the different types of tumor cells and immune cells within TNBC tumors and how they interact with each other. Using biopsies taken before and after treatment, he will document how the tumors have changed. This may yield new ways to treat the cancer.

“Scientific research is the key to finding the answer to all forms of cancer,” said Jill O’Donnell-Tormey, PhD, CRI’s chief executive officer and director of scientific affairs. “The work Drs. Majzner and Meylan are doing holds great promise, and I look forward to seeing how their discoveries will benefit patients in Boston and beyond.”

For more stories about the impact of philanthropy at Dana-Farber, please visit DanaFarberImpact.org.

Less